Key result
Prognostic features including tumor size ≥5 cm, lower extremity location, and poorly differentiated areas ≥20% were significantly associated with adverse outcomes (p<0.001).
Why the study?
Do specific clinical and pathologic features correlate with a poor outcome in patients with extremity synovial sarcoma?
Cohort (n=34)
Do specific clinical and pathologic features correlate with a poor outcome in patients with extremity synovial sarcoma?
In patients with extremity synovial sarcoma, adverse outcomes are associated with increasing age, tumor size ≥5 cm, lower extremity location, poorly differentiated areas, grade 3 nuclei, rhabdoid cells, and >10 MFs/10 HPFs.
No takes yet. Share an insight, caveat, or question.
May aid risk stratification in extremity synovial sarcoma; hypothesis-generating and requires prospective validation.
Machen et al. (1999) conducted a cohort in Synovial sarcoma of the extremities (n=34). Prognostic features including tumor size ≥5 cm, lower extremity location, and poorly differentiated areas ≥20% were significantly associated with adverse outcomes (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: